Arena Pharmaceuticals, Inc.  

(Public, NASDAQ:ARNA)   Watch this stock  
Find more results for ARNA
-0.02 (-0.08%)
Sep 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.72 - 25.17
52 week 11.30 - 27.86
Open 25.12
Vol / Avg. 397,227.00/550,486.00
Mkt cap 984.04M
P/E     -
Div/yield     -
EPS -0.59
Shares 39.22M
Beta 1.37
Inst. own 47%
Nov 6, 2017
Q3 2017 Arena Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 26, 2017
Arena Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference - 2:30PM EDT - Add to calendar
Sep 25, 2017
Arena Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference - 1:15PM EDT - Add to calendar
Sep 7, 2017
Arena Pharmaceuticals Inc at Citi Biotech Conference
Sep 6, 2017
Arena Pharmaceuticals Inc at Wells Fargo Healthcare Conference
Sep 6, 2017
Arena Pharmaceuticals Inc at Liolios Group Gateway Conference
Aug 7, 2017
Q2 2017 Arena Pharmaceuticals Inc Earnings Call - Webcast
Aug 7, 2017
Q2 2017 Arena Pharmaceuticals Inc Earnings Release
Jul 10, 2017
Arena Pharmaceuticals Inc Scientific Update Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -363.77% -18.47%
Operating margin -327.13% -13.83%
EBITD margin - 15.56%
Return on average assets -57.56% -10.75%
Return on average equity -171.00% -48.19%
Employees 106 -
CDP Score - -


6154 Nancy Ridge Dr
SAN DIEGO, CA 92121-3223
United States - Map
+1-858-4537200 (Phone)
+1-858-4537210 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Officers and directors

Amit D. Munshi President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Kevin R. Lind Chief Financial Officer, Principal Financial Officer, Executive Vice President, Principal Accounting Officer
Age: 40
Bio & Compensation  - Reuters
Steven W. Spector J.D. Executive Vice President, General Counsel, Secretary
Age: 51
Bio & Compensation  - Reuters
Vincent E. Aurentz Executive Vice President and Chief Business Officer
Bio & Compensation  - Reuters
Preston S. Klassen M.D. Executive Vice President - Research & Development, Chief Medical Officer
Age: 47
Bio & Compensation  - Reuters
Maurice J. Mezzino Senior Vice President - Corporate Development
Age: 61
Bio & Compensation  - Reuters
Tina Susan Nova Ph.D. Lead Independent Director
Age: 63
Bio & Compensation  - Reuters
Donald D. Belcher Director
Age: 77
Bio & Compensation  - Reuters
Jayson Dallas M.D. Director
Age: 49
Bio & Compensation  - Reuters
Oliver S. Fetzer Ph.D. Director
Age: 53
Bio & Compensation  - Reuters